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chemotaxis is inhibited as a consequence of increased macro-
phage spreading. Macrophage spreading is known to be one 
step of a series which leads to complete macrophage activation 
[28]. What this theory suggests is that TFF init iates an early 
phase in the sequence of macrophage activation and thereby 
immo bilizes them. T his results paradoxically in facilitation of 
tumor development. 
Various degrees of macrop hage activation have been defined. 
Thiolglycollate-activated macrophages, will spread rapidly bu t 
are not tumoricidal unless incubated with endotoxin (29]. How-
ever, macrophages stimulated with BCG, MAF, Toxoplasma 
gondii, or Corynebacterium paruum are cytotoxic to tumor 
cells including Bl6 [29- 32]. T hiolglycollate-induced peri toneal 
macrophages enhance B l 6 tumor development when injected 
s.c. with an inoculum of B l 6 cells (32]. While t he exact level to 
which T FF activates the macrophage is yet to be determined, 
there is a precedent for partial activation of t he macrophages. 
It is not proved that the TFF and the macrophage spreading 
activity a1·e t he same molecule. However , there is a strong 
correlation between macrophage spreading and tumor facili ta-
tion. Both activi ties ar e systemic, and both are effective in nude 
mice. Tumor facilitation, inhibit ion of macrophage accum ula -
tion, and macrophage spread ing m·e all induced by the same 
dose of material. In addi tion, the activit ies are present in both 
Bl6 culture supernatant and B l6 tumor homogenate. T he dose 
response curves for both tumor facilitation in vivo, and macro-
phage spreading in vitro show a supraoptimal range, in which 
the effects of these activit ies are reyersed. Supraopt imal con-
centrations of T FF are not toxic to macrophages in vitro as 
measured by phagocytosis of sheep erythrocytes. F inally, the 
injection of viable Bl6 cells was previously [1] found to fac ili tate 
the development of tumors at distant sites. Macrophage spread-
ing was also induced under t hese condi tions. T hus, both TFF 
and macrophage spreading activi ty ar e produced by Bl6 cells 
in vivo. Although it is not proved that TFF and macrophage 
spreading activity are the same molecule, the correlation be-
tween these activities is strong. 
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